Vitamin E inhibits cyclosporin A and H2O2 promoted Epstein-Barr virus (EBV) transformation of human B cells as assayed by EBV oncogene LMP1 expression

Journal of Surgical Research

Volumn 113, Issue 2, 2003, Pages 228-233

  Chen, Changguo ^a   Reddy, K S ^a   Johnston, T D ^a   Khan, T T ^a   Ranjan, D ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cyclosporin A; Epstein Barr virus; H2O2; Oxidative stress; Post transplant lymphoproliferative disorders (PTLD); Vitamin E (Vit. E)

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CYCLOSPORIN A; HYDROGEN PEROXIDE; LATENT MEMBRANE PROTEIN 1; MARKER; MONOCLONAL ANTIBODY; PHYCOERYTHRIN;

B LYMPHOCYTE; CELL ASSAY; CELL CULTURE; CELL POPULATION; CENTRIFUGATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SCREENING; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE; SPLEEN CELL; STAINING; VIRUS INFECTION; VIRUS ONCOGENE; VIRUS TRANSFORMATION;

EID: 0041882253     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-4804(03)00187-2     Document Type: Conference Paper

References (42)

1. Penn I. Incidence and treatment of neoplasia after transplantation. J. Heart Lung Transplant. 12:1993;S328.
2. Swerdlow S.H. Post-transplant lymphoproliferative disorders a morphologic, phenotypic and genotypic spectrum of disease . Histopathology. 20:1992;373.
3. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., O'Sullivan E.J., Johnson M.R., Heroux A.L., Dizikes G.J., Pifarre R., Fisher R.L. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac- transplant recipients. N. Engl. J. Med. 323:1990;1723.
4. Thomas J.A., Allday M.J., Crawford D.H. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res. 57:1991;329.
5. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., Srivastava D.K., Bowman L.C., Krance R.A., Brenner M.K., Heslop H.E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 92:1998;1549.
6. Teplova V., Evtodienko Y., Odinokova I., Kruglov A., Kudrjavtsev A. Suppression of mitochondrial permeability transition pore and induction of lymphoma P388 cell death by cyclosporin A. IUBMB Life. 50:2000;75.
7. Barth S.A., Inselmann G., Engemann R., Heidemann H.T. Influences of Ginkgo biloba on cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N- acetyleysteine. Biochem. Pharmacol. 41:1991;1521.
8. Longoni B., Boschi E., Demontis G.C., Ratto G.M., Mosca F. Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels. FASEB J. 15:2001;731.
9. Kaye K.M., Izumi K.M., Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA. 90:1993;9150.
10. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 43:1985;831.
11. Ranjan D., Siquijor A., Johnston T.D., Wu G., Nagabhuskahn M. The effect of curcumin on human B-cell immortalization by Epstein-Barr virus. Am. Surg. 64:1998;47.
12. Chen C., Johnston T.D., Reddy K.S., Merrick J.C., Mastrangelo M., Ranjan D. Cyclosporine directly causes oxidative stress and promotes epstein-barr virus transformation of human b cells. J. Surg. Res. 100:2001;166.
13. Ranjan D., Johnston T.D., Reddy K.S., Wu G., Bondada S., Chen C. Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin. J. Surg. Res. 87:1999;1.
14. Caputo J.L., Thompson A., McClintock P., Reid Y.A., Hay R.J. An effective method for establishing human B lymphoblastic cell lines using epstein-Barr virus. J. Tissue Cult. Meth. 13:1991;39.
15. Thorley-Lawson D.A. Basic virological aspects of Epstein-Barr virus infection. Semin. Hematol. 25:1988;247.
16. Swerdlow S.H. Post-transplant lymphoproliferative disorders a morphologic, phenotypic and genotypic spectrum of disease . Histopathology. 20:1992;373.
17. Rogers R.P., Strominger J.L., Speck S.H. Epstein-Barr virus in B lymphocytes viral gene expression and function in latency . Adv. Cancer Res. 58:1992;1.
18. Kanegane H., Yachie A., Miyawaki T., Tosato G. EBV-NK cells interactions and lymphoproliferative disorders. Leuk. Lymphoma. 29:1998;491.
19. Niedobitek G., Young L.S. Epstein-Barr virus persistence and virus-associated tumours. Lancet. 343:1994;333.
20. Niedobitek G., Agathanggelou A., Steven N., Young L.S. Epstein-Barr virus (EBV) in infectious mononucleosis detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells . Mol. Pathol. 53:2000;37.
21. Cruchley A.T., Williams D.M., Niedobitek G., Young L.S. Epstein-Barr virus biology and disease . Oral Dis. 3:1997;S156.
22. Sangueza O.P. Epstein-Barr virus. A serial killer or an innocent bystander? Arch. Dermatol. 133:1997;1156.
23. Smith R.D. Is Epstein-Barr virus a human oncogene or only an innocent bystander? Hum. Pathol. 28:1997;1333.
24. Baumforth K.R., Young L.S., Flavell K.J., Constandinou C., Murray P.G. The Epstein-Barr virus and its association with human cancers. Mol. Pathol. 52:1999;307.
25. Pagano J.S. Epstein-Barr virus the first human tumor virus and its role in cancer . Proc. Assoc. Am. Phys. 111:1999;573.
26. Johannessen I., Crawford D.H. In vivo models for Epstein-Barr virus (EBV)-associated B cell lymphoproliferative disease (BLPD). Rev. Med. Virol. 9:1999;263.
27. Caputo J.L., Thompson A., Mclintotock P., Reid Y.A., Hay R.J. An effective method for establishing human B lymphoblastic cell lines using Epstein-Barr virus. J. Tiss. Culture Meth. 13:1991;39.
28. Khan G., Coates P.J., Kangro H.O., Slavin G. Epstein-Barr virus (EBV) encoded small RNAs targets for detection by in situ hybridisation with oligonucleotide probes . J. Clin. Pathol. 45:1992;616.
29. Ozaki S., Harada K., Watanabe K., Furubo S., Tsui W.M., Nakanuma Y. Absence of Epstein-Barr virus (EBV) in intrahepatic cholangiocarcinoma confirmed by lack of EBV-coded nuclear RNA and latent membrane protein-1. Histopathology. 36:2000;50.
30. Yamamoto T., Nakamura Y., Kishimoto K., Takeuchi H., Shirakata M., Mitsuya T., Hirai K. Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV specific nuclear antigen 1. Virus Res. 65:1999;43.
31. Alfieri C., Birkenbach M., Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 18:1991;595.
32. Kieff, E. Epstein barr virus and its replication. In B. N. Fields (Ed.), Fields Virology. Philadelphia: Lippincott-Raven, 1996.
33. Kilger E., Kieser A., Baumann M., Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17:1998;1700.
34. Devergne O., Hatzivassiliou E., Izumi K.M., Kaye K.M., Kleijnen M.F., Kieff E., Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation role in NF-kappaB activation . Mol. Cell Biol. 16:1996;7098.
35. Brodeur S.R., Cheng G., Baltimore D., Thorley-Lawson D.A. Localization of the major NF-kappaB- activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J. Biol. Chem. 272:1997;19777.
36. Nakagomi H., Dolcetti R., Bejarano M.T., Pisa P., Kiessling R., Masucci M.G. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int. J. Cancer. 57:1994;240.
37. Kenney J.L., Guinness M.E., Curiel T., Lacy J. Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood. 92:1998;1721.
38. Duval C., Poelman M.C. Scavenger effect of vitamin E and derivatives on free radicals generated by photoirradiated pheomelanin. J. Pharm. Sci. 84:1995;107.
39. Auroma, D. Dietary advantages and disadvantages. In J. Scandalios (Ed.), Free Radicals. Boston: Cold Spring Harbor Laboratory Press, 1997.
40. Meydani S.N., Barklund M.P., Liu S., Meydani M., Miller R.A., Cannon J.G., Morrow F.D., Rocklin R., Blumberg J.B. Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. Am. J. Clin. Nutr. 52:1990;557.
41. Yano Y., Yano T., Uchida M., Murakami A., Ogita M., Ichikawa T., Otani S., Hagiwara K. The inhibitory effect of vitamin E on pulmonary polyamine biosynthesis, cell proliferation and carcinogenesis in mice. Biochim. Biophys. Acta. 1356:1997;35.
42. Meydani S.N., Meydani M., Blumberg J.B., Leka L.S., Siber G., Loszewski R., Thompson C., Pedrosa M.C., Diamond R.D., Stollar B.D. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA. 277:1997;1380.